Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages

  Emri, E ^a   Egervari, K ^a   Varvolgyi, T ^a   Rozsa, D ^a   Miko, E ^a   Dezso, B ^a   Veres, I ^a   Mehes, G ^a   Emri, G ^a   Remenyik, E ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD209 ANTIGEN; CD68 ANTIGEN; METALLOTHIONEIN; T6 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA CELL; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR PROMOTION;

ANTIGENS, CD; DISEASE PROGRESSION; FEMALE; HUMANS; MACROPHAGES; MALE; MELANOMA; METALLOTHIONEIN; NEOPLASM METASTASIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84874105827     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04653.x     Document Type: Article

References (31)

1. Agarwala SS,. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010; 20: 1-10.
2. Eggermont AM, Kirkwood JM,. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40: 1825-1836.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
4. Flaherty KT,. Targeting metastatic melanoma. Annu Rev Med 2011; 63: 171-183.
5. Jilaveanu LB, Aziz SA, Kluger HM,. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009; 27: 614-625.
6. Nielsen AE, Bohr A, Penkowa M,. The balance between life and death of cells: roles of metallothioneins. Biomark Insights 2007; 1: 99-111.
7. Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, et al. A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol 2011; 9: 54.
8. Cherian MG, Jayasurya A, Bay BH,. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
9. Moore DA, Howard Pringle J, Saldanha GS,. Prognostic tissue markers in melanoma. Histopathology 2012; 60: 679-689.
10. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
11. Pacifico MD, Grover R, Richman P, et al. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 2004; 14: 39-42.
12. McGee HM, Woods GM, Bennett B, Chung RS,. The two faces of metallothionein in carcinogenesis: photoprotection against UVR-induced cancer and promotion of tumour survival. Photochem Photobiol Sci 2010; 9: 586-596.
13. Fried L, Arbiser JL,. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008; 21: 117-122.
14. Pedersen MO, Larsen A, Stoltenberg M, Penkowa M,. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009; 44: 29-64.
15. Das K, Mohd Omar MF, Ong CW, et al. TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology 2008; 40: 441-449.
16. Jensen TO, Riber-Hansen R, Schmidt H, et al. Tumor and inflammation markers in melanoma using tissue microarrays: a validation study. Melanoma Res 2011; 21: 509-515.
17. Ablett E, Whiteman DC, Boyle GM, et al. Induction of metallothionein in human skin by routine exposure to sunlight: evidence for a systemic response and enhanced induction at certain body sites. J Invest Dermatol 2003; 120: 318-324.
18. Poulsen CB, Borup R, Borregaard N, et al. Prognostic significance of metallothionein in B-cell lymphomas. Blood 2006; 108: 3514-3519.
19. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56: 1459-1469.
20. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-268.
21. + counterparts. Int Immunol 2007; 19: 1271-1279.
22. Penkowa M,. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J 2006; 273: 1857-1870.
23. Penkowa M, Espejo C, Martinez-Caceres EM, et al. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 119: 248-260.
24. Penkowa M, Hidalgo J,. Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia 2000; 32: 247-263.
25. Penkowa M, Hidalgo J,. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol 2001; 170: 1-14.
26. Giralt M, Penkowa M, Lago N, et al. Metallothionein-1 + 2 protect the CNS after a focal brain injury. Exp Neurol 2002; 173: 114-128.
27. Pankhurst MW, Bennett W, Kirkcaldie MT, et al. Increased circulating leukocyte numbers and altered macrophage phenotype correlate with the altered immune response to brain injury in metallothionein (MT)-I/II null mutant mice. J Neuroinflamm 2011; 8: 172.
28. Talmadge JE, Donkor M, Scholar E,. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007; 26: 373-400.
29. Solinas G, Germano G, Mantovani A, Allavena P,. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073.
30. Schmieder A, Michel J, Schonhaar K, et al. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012; 22: 289-297.
31. Pena OM, Pistolic J, Raj D, et al. Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol 2011; 186: 7243-7254.